Moderna Inc.
Moderna Announces Board Changes with Appointment of David Rubenstein and Departures of Robert Langer and Stephen Berenson
Summary
On July 19, 2024, Moderna, Inc. announced via an 8-K filing that Robert Langer and Stephen Berenson will resign from the Board of Directors, effective August 5, 2024. Simultaneously, the Board appointed David M. Rubenstein, Co-Founder and Co-Chairman of The Carlyle Group, to the Board, effective the same date. Rubenstein will also serve on the Audit Committee. Both departing directors will provide consulting services to Moderna. The information was also disclosed in a press release dated July 23, 2024, furnished as Exhibit 99.1.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement